Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus for Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. Hoosier Oncology Group GU09-145 (Kidney)
ID Number 10-1591
Principal Investigator(s)Matthew Galsky
Department(s) or Division(s)
Hematology and Medical Oncology
Medicine
Description
The purpose of this study is to test a new cancer treatment drug called BNC 105P in combination with everolimus to see what effects (good and bad) it has on patients and their cancer.
Individuals may qualify to take part in this research study because they have been diagnosed with clear cell renal cancer that has spread to other organs in their body. Renal cell carcinoma is the cancer that develops in the kidneys.
The study drug, BNC105P, is made by Bionomics Ltd, a biotech company in Australia, and is an experimental drug. BNC105P is a drug that causes changes in the lining of the blood vessels nourishing the tumor cells more than the lining of the blood vessels nourishing the normal cells. These changes are responsible for the decrease of blood flow to the tumor, which is resulting in death of the tumor cells and reduction of the tumor size. It is different from the other drugs in the market in a way that it shuts down tumor blood vessels "locking itself" inside the tumor where it acts on the tumor cells resulting in tumor cell death. BNC105P is not available for one to buy ("on the market"). It is only available in research studies for patients with a medical condition.
Everolimus has been approved by the FDA and for the treatment of renal cancer following treatment with the chemotherapies such as Sutent or Sorafenib.
Contact Information
Matthew Galsky
(212) 241-6756
Recruiting Patients: Yes